Coeliac disease is an autoimmune disorder in which gluten, a protein found in wheat, barley and rye, triggers an abnormal immune response in genetically susceptible individuals. This immune activation results in inflammation and progressive damage to the lining of the small intestine, leading to complications including osteoporosis, infertility, nutritional deficiencies and an increased risk of certain gastrointestinal cancers if left untreated.  

Until recently, it was believed that intestinal damage occurred only after exposure to relatively large amounts of gluten. Studies have shown that consuming between 3,000 and 6,0000mg of gluten daily for two weeks, or as little as 50 mg daily over three months, can result in measurable injury to the small intestine. These findings have formed the basis of current international dietary recommendations and food-labelling standards.  

Our research has fundamentally challenged this understanding. In a recent clinical study, we demonstrated for the first time that even extremely small amounts of gluten — as little as 3 mg, approximately one-one thousandth of a slice of bread — can trigger a measurable immune response in people with well-treated coeliac disease. Importantly, the same biological pathway was activated across a range of gluten doses, from 3 mg through to 1,000 mg, suggesting that the immune system recognises even microgram quantities of gluten.  

This finding raises a critical unanswered question: does repeated exposure to these very small amounts of gluten, below levels currently considered acceptable by many international food standards, cause cumulative intestinal injury over time? To answer this question, we will undertake comprehensive immune profiling of previously collected samples using ultra-sensitive cytokine detection platforms, providing important new insights into how the immune system responds to repeated low-level gluten exposure, potentially triggering intestinal damage over time. 

Impact

The findings have the potential to reshape our understanding of what constitutes a safe level of gluten exposure for people living with coeliac disease. By generating the first detailed molecular map of immune responses to micro-dose gluten exposure, this research could directly inform future international food-labelling regulations, improve dietary recommendations, guide the development of sensitive biomarkers of disease activity, and ultimately reduce the burden of ongoing intestinal injury experienced by millions of people worldwide despite their best efforts to follow a gluten-free diet.  

Recruitment

Our recently completed gluten threshold study collected serial blood samples before and after carefully controlled gluten challenges across a wide range of gluten doses. This biobank provides an opportunity to investigate the body’s immune response to micro-dose gluten exposure. We are not recruiting for this study.